Loading…
Tumour Suppressor Protein (p53), Apoptosis Inhibiting Protein (Bcl-2) and Proliferating Cell Nuclear Antigen (PCNA) Expressions in a Rat Pancreatic Tumour Model
Background: Previous studies have shown that, cultured rat pancreatic carcinoma cells, derived from azaserine-induced acinar tumours, yield tumours with a ductal phenotype. Materials and Methods: In order to find out the molecular characteristics of this tumour model, tumour suppressor protein (p53)...
Saved in:
Published in: | Anticancer research 2007-01, Vol.27 (1A), p.23-26 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background: Previous studies have shown that, cultured rat pancreatic carcinoma cells, derived from azaserine-induced acinar
tumours, yield tumours with a ductal phenotype. Materials and Methods: In order to find out the molecular characteristics
of this tumour model, tumour suppressor protein (p53), apoptosis inhibiting protein (Bcl-2) and proliferating cell nuclear
antigen (PCNA) expressions were analysed in rat pancreatic and subcutaneous tumours, as well as in normal rat pancreas. Results:
Immunoreactivity for p53 protein was found in 86% of intrapancreatic tumours and in 100% of subcutaneous tumours. The average
fraction of positive carcinoma cells was over 50%. Normal rat pancreas showed only slight positive or negative staining for
p53. Bcl-2 did not show positive immunoreactivity in rat tumour samples. For PCNA all tumour samples showed positive staining.
Also normal pancreas of 6-week-old animals were clearly positive, whereas the samples of the older animals were only slightly
positive. Conclusion: Possible mutations in the p53 tumour suppressor gene and a strong expression of PCNA were shown in carcinoma
cell line-induced rat pancreatic tumours. These features of the rat pancreatic tumour model resemble human pancreatic carcinoma
and may favour the use of this model in pancreatic cancer studies. |
---|---|
ISSN: | 0250-7005 1791-7530 |